MECOM and acute myeloid leukemia: In the most recent 2022 edition, this exception now extends to all AML subtypes with recurrent genetic abnormalities including AML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2Ac, t(6;9)(p22.3;q34.1)/DEK::NUP214, inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2, MECOM(EVI1), other rare recurring translocations, and mutated NPM1. While the ICC still requires a blast percentage of ≥ 10% in the setting of a genetically-defining lesion, the WHO does not include a lower limit in its definition of genetically-defined AML.